{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:49:11Z","timestamp":1791920951656,"version":"4.3.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jiac.2020.12.021","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T03:30:07Z","timestamp":1609126207000},"page":"390-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19"],"prefix":"10.1016","volume":"27","author":[{"given":"Shingo","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-9420","authenticated-orcid":false,"given":"Takaaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Sayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taka-aki","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Igari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2020.12.021_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","author":"Du","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2020.12.021_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.jiac.2020.12.021_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.jiac.2020.12.021_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.jiac.2020.12.021_bib5","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2020.12.021_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiac.2020.12.021_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"Madelain","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2020.12.021_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jiac.2020.12.021_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/pathogens9060430","article-title":"SARS-CoV-2 infection and the liver","volume":"9","author":"Morgan","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.jiac.2020.12.021_bib10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/liv.14435","article-title":"Liver injury during highly pathogenic human coronavirus infections","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int"},{"issue":"20","key":"10.1016\/j.jiac.2020.12.021_bib11","first-page":"30377","article-title":"COVID-19 and the liver","volume":"S0168\u20138278","author":"Jothimani","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jiac.2020.12.021_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2020.12.021_bib13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","article-title":"Liver injury in COVID-19: management and challenges","volume":"5","author":"Zhang","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20304566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20304566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:02:55Z","timestamp":1761159775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X20304566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1341321X20304566"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2020.12.021","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2020.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}